Muromonab

DB00075ApprovedInvestigationalWithdrawnProtein Based TherapiesCD3 Blocker Immunosuppressant

Muromonab is a monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients. Murine monoclonal antibody specific to CD3 T-cell lymphocyte antigens.

Protein structure of Muromonab

Mechanism: Muromonab binds to the T-cell surface glycoprotein CD3 epsilon chain. It appears to kill CD-3 positive cells by inducing Fc mediated apoptosis, antibody mediated cytotoxicity and complement-dependent cytotoxicity.
Curator reviewed
Primary indication: For treatment of organ transplant recipients, prevention of organ rejectionCurator reviewed · 3 structured indications
Formula / weight: C₆₄₆₀H₉₉₄₆N₁₇₂₀O₂₀₄₃S₅₆ · 146189.7 Da
First approval: Canada, 1998 · United States, 1986
Also known as: Anti-CD3 · Muromonab-CD3

Resolves to

Compound

UNIIJGA39ICE2VCAS140608-64-6ChEMBLCHEMBL1201608KEGGD05092

Clinical / RWD

RxNorm42405ATCL04AG01PharmGKBPA164743097

Targets

P04234CD3DP07766CD3EP09693CD3GP20963CD247O75015FCGR3B

What you can answer from here — as of July 17, 2026

5Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

688Drug interactionsStructured to mechanism, not free text

83Clinical trialsPhase, status and sponsor resolved per trial

3Structured indicationsCondition, population, route and combination as fields, not prose

2Marketed productsAcross 2 countries and 2 labellers

1ATC codeIncluding every combination product, plus 21 drug categories

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Muromonab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Log In Paid Account Log In